Jennifer Castro
Director of Translational and Discovery Biology Accent Therapeutics
Seminars
Thursday 29th January 2026
Introducing DHX9 & ATX-559 as a Novel DDR Program to Broaden Therapeutic Opportunities in Early-Phase Trials
2:00 pm
• See how Accent Therapeutics is pioneering DHX9-targeted therapy with their lead compound ATX-559
• Outlining the Phase 1 trial dose-escalation design and key study objectives
• Sharing translational insights from preclinical data, including biomarker strategy and combination potential to guide future development
